The Rapid AML Therapeutic Panel analyzes 13 biomarkers through a combination of bi-directional Sanger sequencing, fragment analysis, and FISH as listed below.
- Sanger sequencing (6 genes): FLT3 (ITD and TKD), NPM1, CEBPA, IDH1/IDH2, and TP53.
- FISH probes: 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (Cen 7, 7q22, 7q31) | RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | MLL (11q23) | PML/RARA t(15;17) | CBFB inv(16), t(16;16) | 17p- (TP53 17p13.1, NF1 17q11.2)
Test reports include a summary of all results together.
The Rapid AML Therapeutic Panel identifies genetic abnormalities associated with Acute Myeloid Leukemia (AML) that are useful for risk stratification and therapeutic decision making. This panel utilizes a combination of bi-directional Sanger sequencing, fragment analysis and FISH with a fast turnaround time. AML is usually an in-patient hematologic diagnosis and prompt time to treatment assignment can improve patient outcomes significantly.
- Bone Marrow Aspirate: 2-3 mL sodium heparin tube. EDTA tube is acceptable.
- Peripheral Blood: 3-5 mL sodium heparin tube. EDTA tube is acceptable.
- Fluids: Equal parts RPMI to specimen volume.
- Note: Please exclude biopsy needles, blades, and other foreign objects from transport tubes. These can compromise specimen viability and yield, and create hazards for employees.
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.
4-5 Days for FLT3, IDH1/IDH2, and FISH. 7-10 Days for NPM1, CEBPA, and TP53.